Pharma major, Biocon Pharma, has received final approvals from the U.S. Food and Drug Administration (FDA) for its ...

The rise in Biocon share price came after the company announced that its wholly-owned subsidiary, Biocon Pharma, has received ...

Biocon rose 1.08% to Rs 318.20 after the company said that Biocon Pharmahas received final approvals from the U.S. Food and Drug Administration (FDA) for its abbreviated new drug applications (ANDAs) ...

The company announced that it has secured three orders valued at around ₹500 crore from Power Grid Corporation of India Ltd ...

Stocks like Ola Electric Mobility, Grasim Industries, RHI Magnesita India, Apollo Hospitals Enterprise, Walchandnagar ...

The FDA has accepted the resubmission of the BLA of Ordspono for review in relapsed/refractory follicular lymphoma following previous systemic therapy.

Eli Lilly said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended expanded approval of its Jaypirca cancer drug in certain patients with chronic lymphocytic ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study 1,2 ; DLBCL-an ...

Guggenheim analyst Michael Schmidt raised the firm’s price target on BeiGene (ONC) to $348 from $345 and keeps a Buy rating on the shares after ...

Panelists discuss how clinical and patient-specific factors, such as comorbidities, age, and risk profiles, influence the selection of Bruton tyrosine kinase (BTK) inhibitors for treatment-naive ...

Panelists discuss how Bruton tyrosine kinase (BTK) inhibitors have transformed the treatment paradigm for patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), especially in ...

Hematopoietic and lymphocytic neoplasms (HLNs) are a diverse group of malignancies affecting blood and lymphatic systems, with outcomes varying from manageable conditions to fatal diseases.